Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams
In a Nutshell
Dr. Nolan Williams argues that psychiatric illnesses like depression and PTSD reflect dysfunctional brain circuits that can be rapidly rewired rather than permanent chemical or developmental deficits. TMS and psychedelics (psilocybin, MDMA, ibogaine) both produce fast, lasting symptom relief by altering subgenual-default mode network connectivity and enabling memory reconsolidation under enhanced plasticity. Stanford Neuromodulation Therapy achieves 60–90% remission in 1–5 days by delivering intensive, spaced prefrontal stimulation that mimics these circuit-level changes.
These notes were generated by AI and may contain inaccuracies.
Depression is the most disabling condition worldwide. It functions as both a risk factor for other illnesses and makes other medical and psychiatric illnesses worse. The American Heart Association added depression as the fourth major risk factor for coronary artery disease, alongside hypertension, hyperlipidemia, and diabetes.
Transcranial magnetic stimulation (TMS) can decelerate heart rate when applied over mood regulatory regions. This provides a direct probe of brain-heart connections. The first place stimulation goes is the dorsolateral prefrontal cortex, described as the sense of control or governor of the brain.
Using Faraday's law, a magnetic pulse induces an electrical current in brain tissue, avoiding skull, scalp, and hair. This causes direct depolarization of cortical neurons in the dorsal prefrontal area. In the scanner, this activity distributes down into the anterior cingulate, insula, amygdala, and ultimately into the nucleus tractus solitarius and vagus nerve into the heart.
The heart is the end organ of the dorsolateral prefrontal cortex. This effect is specific to the control region and does not occur with stimulation over visual cortex or motor cortex. The connection has been replicated four to five times.
Patients report that after TMS treatment, they can understand their therapy books and materials in ways they could not before. TMS provides exogenous cognitive functions that milder depression allows through psychotherapy. In depression, deeper regions govern the prefrontal cortex rather than the reverse.
Depression involves spontaneous content generated from the conflict detection system in the cingulate. The left dorsolateral prefrontal cortex fails to sufficiently clamp down on it. TMS restores governance of the left dorsolateral region over the cingulate area, and the degree of retiming correlates with antidepressant effect.
TMS functions like exercise for the brain by repeatedly applying a physiologically relevant signal.
Some patients who remit early in the five-day dense TMS protocol report spontaneous mindfulness experiences. One patient described sitting at the beach and being totally present for an hour. Multiple patients have reported similar present-moment experiences by the end of the week.
SSRIs are effective for obsessive-compulsive disorder, depression, generalized anxiety disorder, and panic. Meta-analyses confirm benefit in a subpopulation of individuals.
SSRIs do not work immediately, suggesting the mechanism is not direct serotonin elevation. There is no serotonin deficit. The chemical imbalance concept is incorrect. Psychiatry has known this, though it has been reframed in the lay press.
Psychiatry 1.0 refers to Freudian psychotherapy focused on family experiences and correcting cognitions. Psychiatry 2.0 refers to the chemical imbalance model, which sends the message that something is missing in the patient.
Psychiatry 3.0 focuses on circuitry. TMS works without adding serotonin and achieves effects in one to five days, pushing back on the serotonin hypothesis. The focus shifts to turning brain regions on and modulating circuits.
Neuroimaging shows circuit-level changes after psilocybin or ketamine long after the drug is gone. The subgenual default mode network connection changes with Stanford neuromodulation therapy and also with ketamine and psilocybin.
This framework emphasizes that psychiatric illnesses are recoverable rather than permanent deficits from childhood experiences or chemical imbalances.
In PTSD, symptoms that are maladaptive in civilian life were highly adaptive in combat. Psychedelics including MDMA and psilocybin appear to alleviate symptoms that otherwise persist.
The mechanism may involve entering a highly plastic state, reexperiencing memories, and reconsolidating them in that state.
The pragmatic approach is to use treatments if trials demonstrate therapeutic effect, regardless of cultural baggage.
In clinical settings, MDMA appears to produce anti-PTSD effects after one to a few sessions. The standard MAPS dose is 150 to 175 milligrams administered with physician oversight.
Approximately two-thirds of people with trauma experience clinically significant change in PTSD symptoms. Earlier trials showed effects lasting in the years range for some individuals.
Ketamine effects last on average one and a half weeks per infusion, requiring repeated dosing for some patients.
In open-label studies, half to two-thirds of people experience improvement depending on treatment resistance level. In blinded trials, approximately one-third of people improve.
David Nutt and Robin Carhart-Harris conducted early neuroimaging work. Contrary to expectation, psychedelics produce an overall decrease in brain activity level. Global connectivity increases while small-world connectivity patterns shift.
Psilocybin produces a connectivity change between the subgenual anterior cingulate and the default mode network, matching changes seen with Stanford neuromodulation therapy. An overconnected negatively valenced system attached to self-representation becomes unpaired.
Ibogaine is an alkaloid extracted from iboga tree root bark native to Gabon, Africa. With eyes open, users see nothing, but with eyes closed they reexperience earlier life memories from a detached, empathic perspective, viewing events almost as a third party.
Ibogaine is not recreational. Users describe it as a life review or ten years of psychotherapy in a night. Duration ranges from 24 to 36 hours depending on metabolism.
Ibogaine is the longest-acting psychedelic substance known. It carries cardiac risk that can be screened via electrocardiogram.
A first-in-human neurobiological clinical and neurocognitive evaluation of ibogaine is underway in former Navy SEALs and Army Rangers. Assessments include depression and PTSD scales, neurocognitive batteries measuring executive function and verbal memory, neuroimaging, and EEG.
Patients report dramatic improvement. Soldiers describe relief from moral injury, the experience of accidentally causing civilian or child deaths. They report forgiving themselves after gaining empathy for themselves through the experience.
Psychedelics carry a Timothy Leary-style sociocultural overlay from the counterculture movement. Removing preconceived notions and examining these compounds as if newly discovered reveals their potential as major psychiatric breakthroughs. They combine elements of SSRIs and psychotherapy by enabling re-examination of mental patterns in altered states that normal waking consciousness cannot access.
Current evidence does not yet confirm this hypothesis, and substantial additional research is required. If validated, these substances would represent a breakthrough precisely because they facilitate therapeutic processes impossible under ordinary consciousness.
Psychedelics are too powerful for recreational use. The current generation of researchers emphasizes strict medical oversight, contrasting with 1960s approaches. Since SSRIs—which produce minimal consciousness changes—require weekly physician evaluation, more potent consciousness-altering substances demand even greater protection. Proper implementation requires protocols ensuring these compounds serve exclusively therapeutic purposes for powerful, temporary cognitive change.
Ayahuasca functions as a sacrament in Brazil, Peru, Ecuador, and Colombia. It combines two Amazonian plants: one containing dimethyltryptamine (DMT) and another providing a reversible monoamine oxidase inhibitor (MAOI). Among approximately 10,000–20,000 Amazonian plant species, indigenous practitioners identified the specific pairing and five-to-ten-hour cooking process that allows oral DMT to cross the blood-brain barrier. The reversible MAOI prevents gastrointestinal breakdown of DMT without triggering serotonin syndrome, unlike irreversible pharmaceutical MAOIs.
Studies by a UCLA Harbor psychiatrist found no neurocognitive effects in children or adults exposed to small ceremonial doses within Amazonian tribes. Ayahuasca has merged with Catholicism in certain Brazilian sects, where it serves as a religious sacrament. Brazilian researchers investigated its potential for reducing prisoner recidivism by administering ayahuasca sessions versus inert substances. The ayahuasca group showed statistically significantly lower return-to-prison rates, suggesting impact on factors driving criminal behavior.
Stanford accelerated intelligent neuromodulation therapy, now called Stanford neuromodulation therapy, applies spaced learning theory to transcranial magnetic stimulation (TMS). Traditional TMS delivers one session daily, five days weekly for six weeks. SNT condenses the equivalent of seven-and-a-half months of standard dosing into five days by delivering stimulation hourly for ten hours each day—a 50-hour block containing 90 minutes of actual stimulation.
This approach yields full remission rates between 60% and 90% within one to five days, with some patients maintaining remission for one to four years. The protocol sends a repeated "turn on, stay on" signal directly into the prefrontal cortex, bypassing typical hippocampal mediation. Patients report no side effects and a return to normal feeling upon completion.
The discussion covered depression neurocircuitry, depression subtypes, therapeutic compounds and mechanisms, and emerging interventions aimed at reducing suicidal depression through targeted mental health approaches.
Keep Andrew Huberman in your library
Save the videos and channels worth coming back to, and find them again in one place.
